What is the 13F Pro Quality Score for LNSR?

13F Pro ranks LENSAR, Inc. (LNSR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LNSR's current score at https://13fpro.ai/company/LNSR (free sign-up required for the full ranking).

Where does 13F Pro source LNSR data?

All LENSAR, Inc. fundamentals and ownership data come directly from SEC EDGAR. LENSAR, Inc. files with the SEC under CIK 1320350. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LNSR in?

LENSAR, Inc. (LNSR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LNSR research updated on 13F Pro?

LNSR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

LENSAR, Inc.(LNSR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1320350 LNSR stock profile & AI dashboard →

13F Pro Quality Score

53.7/100

Rank #1,377 of 2,962 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

72.9/100

Profitability

98.6/100

Balance Sheet

99.5/100

Earnings Quality

42.1/100

Free Cash Flow

15.5/100

Institutional Flow

6.4/100

Revenue Scale

10.6/100

Dilution Risk

23.9/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why LNSR Scores 54/100

exact factor attribution · 2026-09-11

LNSR's composite is driven by profitability and capital efficiency, held back by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Profitability

+7.3 pts

99th pct

Capital efficiency

+5.0 pts

100th pct

Revenue growth

+4.6 pts

73th pct

Earnings growth

+2.3 pts

95th pct

Earnings quality

-0.8 pts

42th pct

Shareholder dilution

-1.3 pts

24th pct

Institutional flow

-2.2 pts

6th pct

Free cash flow

-5.2 pts

16th pct

Scale

-5.9 pts

11th pct

Latest change (2026-08-13): 51 → 35 · ↓ Profit margin 72→35; ↓ Capital efficiency 70→25

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in LNSR

Events flagged as statistical outliers against LNSR's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-13
LNSR quality score dropped 16 points (51→34) on a new filing
View source filing →

LNSR Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for LENSAR, Inc. (LNSR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LNSR at 53.7/100 on a 32-signal composite quality model, placing it at rank #1,377 of 2,962 stocks — the top half of the AI-ranked universe. LNSR scores in the top quartile across balance sheet strength (99.5), profitability (98.6). Areas of concern include institutional flow (6.4) and revenue scale (10.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 23.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), LENSAR, Inc. reports quarterly revenue of $16.5M, net income of $3.5M. Top institutional holders of LNSR by reported 13-F value include BRANDES INVESTMENT PARTNERS, VANGUARD CAPITAL MANAGEMENT, Groupe la Francaise, based on the most recent SEC filings. LNSR trades on the Nasdaq exchange and files with the SEC under CIK 1320350. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LNSR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LENSAR, Inc. directly from SEC EDGAR. LENSAR, Inc.'s 13F Pro composite quality score has ranged between 17 and 54 since 2022, currently 53.7 — an improving long-term trajectory across 64 quarterly and live scoring snapshots.

✦

Fun facts about LENSAR, Inc.

Quirks, history, and lore behind LNSR — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on Nasdaq · headquartered in Florida.
2
The Numbers
Annual revenue in the range of tens of millions of dollars — this is a niche specialist, not a sprawling healthcare giant, with a market cap well under $200 million.
3
The History
The company was spun out of Pfizer and has focused its entire existence on a single surgical subspecialty: eye surgery.
4
The Secret
Its core technology uses a femtosecond laser to automate the most delicate steps of cataract surgery, replacing the traditional manual blade with sub-micron precision.
5
The Lore
Its laser system integrates 3D imaging and artificial intelligence to guide the surgeon in real time — essentially turning a routine eye procedure into a robotic operation.
6
The Giveaway
The name is literally a mashup of "lens" and "laser" — because that is exactly, and only, what this Orlando company does to your cataracts.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$16.5M

Net Income

Q2 2026

$3.5M

ROIC

Q2 2026

57.3%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+9.2% YoY

$58.4MFY 2025

FY22 $35.4MFY23 $42.2MFY24 $53.5MFY25 $58.4M

Net Income

-9.2% YoY

$-34.3MFY 2025

FY22 $-19.9MFY23 $-14.4MFY24 $-31.4MFY25 $-34.3M

Operating Income

-130.5% YoY

$-24.6MFY 2025

FY22 $-20.2MFY23 $-12.2MFY24 $-10.7MFY25 $-24.6M

EPS (Diluted)

-5.1% YoY

$-2.87FY 2025

FY22 $-1.96FY23 $-1.31FY24 $-2.73FY25 $-2.87

Total Assets

+7.7% YoY

$71.4MFY 2025

FY22 $55.8MFY23 $69.6MFY24 $66.3MFY25 $71.4M

Op. Cash Flow

-551.9% YoY

$-14.8MFY 2025

FY22 $-14.9MFY23 $-9.7MFY24 $-2.3MFY25 $-14.8M

Free Cash Flow

-513.5% YoY

$-14.9MFY 2025

FY22 $-15.0MFY23 $-9.9MFY24 $-2.4MFY25 $-14.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$58.4M +9.2%	$53.5M +26.9%	$42.2M +19.2%	$35.4M +2.6%	$34.5M +30.6%	$26.4M
Net Income	$-34.3M -9.2%	$-31.4M -118.3%	$-14.4M +27.8%	$-19.9M -1.6%	$-19.6M +0.9%	$-19.8M
Operating Income	$-24.6M -130.5%	$-10.7M +12.8%	$-12.2M +39.4%	$-20.2M -2.7%	$-19.7M -6.2%	$-18.5M
EPS (Diluted)	$-2.87 -5.1%	$-2.73 -108.4%	$-1.31 +33.2%	$-1.96 +6.2%	$-2.09	—
Total Assets	$71.4M +7.7%	$66.3M -4.7%	$69.6M +24.6%	$55.8M -16.0%	$66.5M -16.0%	$79.1M
Operating Cash Flow	$-14.8M -551.9%	$-2.3M +76.4%	$-9.7M +35.0%	$-14.9M -65.6%	$-9.0M +35.0%	$-13.8M
Free Cash Flow	$-14.9M -513.5%	$-2.4M +75.4%	$-9.9M +33.9%	$-15.0M -60.6%	$-9.3M +34.1%	$-14.2M

Get alerted when LNSR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for LENSAR, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LNSR

BRANDES INVESTMENT PARTNERS, LP
$6.1M1,075,400 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.3M402,806 sh
Groupe la Francaise
$1.2M213,537 sh
RBF Capital, LLC
$1.1M188,661 sh
BlackRock, Inc.
$1.1M185,033 sh
CSS LLC/IL
$933.3K163,450 sh
DIMENSIONAL FUND ADVISORS LP
$865.7K151,609 sh
CREDIT INDUSTRIEL ET COMMERCIAL
$824.3K144,359 sh
Kerrisdale Advisers, LLC
$795.9K139,390 sh
MILLENNIUM MANAGEMENT LLC
$689.1K120,680 sh

Fund	Value	Shares
BRANDES INVESTMENT PARTNERS, LP	$6.1M	1,075,400
VANGUARD CAPITAL MANAGEMENT LLC	$2.3M	402,806
Groupe la Francaise	$1.2M	213,537
RBF Capital, LLC	$1.1M	188,661
BlackRock, Inc.	$1.1M	185,033
CSS LLC/IL	$933.3K	163,450
DIMENSIONAL FUND ADVISORS LP	$865.7K	151,609
CREDIT INDUSTRIEL ET COMMERCIAL	$824.3K	144,359
Kerrisdale Advisers, LLC	$795.9K	139,390
MILLENNIUM MANAGEMENT LLC	$689.1K	120,680

Companies Similar to LNSR

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

INMD

InMode Ltd.

AI score

Similar quality profile · 3 shared holders

RBF Capital, LLC Yakira Capital Management, Inc.Legato Capital Management LLC

APT

ALPHA PRO TECH LTD

AI score

Similar quality profile · 1 shared holders

ESSEX INVESTMENT MANAGEMENT CO LLC

SRTA

Strata Critical Medical, Inc.

AI score

Similar quality profile

UTMD

UTAH MEDICAL PRODUCTS INC

AI score

Similar quality profile · 1 shared holders

BRANDES INVESTMENT PARTNERS, LP

GSK

GSK plc

AI score

Similar quality profile · 1 shared holders

BRANDES INVESTMENT PARTNERS, LP

EMBC

Embecta Corp.

AI score

Similar quality profile · 2 shared holders

Groupe la Francaise Blume Capital Management, Inc.

TECH

BIO-TECHNE Corp

AI score

Similar quality profile · 1 shared holders

Alpine Global Management, LLC

KYNB

KYNTRA BIO, INC.

AI score

Similar quality profile

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LNSR on your watchlist

Track score changes the day LENSAR, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LNSR a good stock to buy?

13F Pro's AI-powered analysis of LENSAR, Inc. (LNSR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LNSR are available on the LNSR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. LNSR is classified as a small company.

Which hedge funds own LNSR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LNSR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of LENSAR, Inc.'s investment landscape.